Journal of Oral and Maxillofacial Surgery最新文献_第7页

Subspeciality Leadership in ACPA Approved Cleft and Craniofacial Teams in the United States 美国 ACPA 批准的裂隙和颅面团队的亚专科领导力

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.08.046

Caitlin B.L. Magraw MD, DDS, FACS, Caitlin B.L. Magraw MD, DDS, FACS (Presenter)

引用次数: 0

Are More Medically Complex Patients Who Undergo Complex Septorhinoplasty at an Increased Risk for Surgical Site Infection? 接受复杂鼻中隔成形术的患者病情更复杂，手术部位感染的风险是否会增加？

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.07.004

Scott Cannon DMD, MD , Brian R. Carr DMD, MD , Timothy W. Neal DDS, MD , Patricia Sarcos DMD, MD , Scott Bueno DDS, MD , Richard A. Finn DDS

Background

Prophylactic antibiotics are routinely prescribed by surgeons for their patients who undergo septorhinoplasty. However, the literature to support this remains controversial, especially in complex cases, those that require grafts, revision cases, extended surgical time, and an American Society of Anesthesiologists (ASA) value greater than or equal to 3.

Purpose

The study purpose was to evaluate for a potential association between increased anesthetic complexity and the risk for surgical site infection (SSI) following complex septorhinoplasty.

Study Design, Setting, Sample

Retrospective cohort study of patients who underwent a complex septorhinoplasty between 2005 and 2022 at the Dallas Veterans Affairs Medical Center. Patients were excluded if they did receive a septorhinoplasty, did not follow up, or had insufficient records.

Independent Variable

All patients were assigned an ASA value prior to surgery, with an ASA value of 3 serving as this study's independent variable.

Main Outcome Variable

The main outcome variable of interest was the development of a postoperative SSI, defined as findings consistent with cellulitis, purulence, or fistula development necessitating antibiotic treatment.

Covariates

The demographic covariates included patient age and sex. Clinical covariates included diabetes status, history of nasal trauma or surgery, and smoking status. The operative covariates were surgical duration, perioperative antibiotic, intraoperative complication, and type of cartilage graft used.

Analyses

χ² Analysis and t-tests were used for calculations, with P values < .05 being considered significant.

Results

A total of 182 patients were included in this study, 81 (45%) with an ASA ≤2 and 101 (55%) with an ASA of 3. A patient's age (P < .01), male sex (P < .01), and a diagnosis of diabetes (P < .01) were associated with an ASA value of 3. In total, there were 6 (3.3%) SSIs, with 2 (1%) occurring in those with an ASA of 3. An ASA value of 3 (P = .27, relative risk of .40) was not shown to be associated with an increased risk of SSI.

Conclusion and Relevance

Our results suggest that an ASA of 3 is not significant with regard to postoperative infection in patients who undergo a complex nasal septorhinoplasty, and prophylactic postoperative antibiotics are not warranted.

背景外科医生通常会为接受鼻中隔成形术的患者开具预防性抗生素处方。然而，支持这种做法的文献仍存在争议，尤其是在复杂病例、需要移植物的病例、翻修病例、手术时间延长以及美国麻醉医师协会（ASA）值大于或等于 3 的病例中。研究设计、设置、样本对 2005 年至 2022 年期间在达拉斯退伍军人事务医疗中心接受复杂鼻中隔成形术的患者进行了回顾性队列研究。自变量所有患者在手术前都被分配了一个 ASA 值，其中 ASA 值为 3 的患者是本研究的自变量。主要结果变量主要结果变量是术后 SSI 的发生情况，定义为蜂窝织炎、化脓或瘘管的发生，需要抗生素治疗。临床协变量包括糖尿病状况、鼻部外伤或手术史以及吸烟状况。手术协变量包括手术时间、围手术期抗生素、术中并发症和使用的软骨移植类型。结果本研究共纳入 182 例患者，其中 81 例（45%）ASA ≤2，101 例（55%）ASA 为 3。患者的年龄（P < .01）、性别（P < .01）和糖尿病诊断（P < .ASA 值为 3（P = 0.27，相对风险为 0.40）与 SSI 风险增加无关。结论和意义我们的研究结果表明，ASA 值为 3 的复杂鼻中隔成形术患者术后感染的几率并不大，因此术后无需预防性使用抗生素。

{"title":"Are More Medically Complex Patients Who Undergo Complex Septorhinoplasty at an Increased Risk for Surgical Site Infection?","authors":"Scott Cannon DMD, MD , Brian R. Carr DMD, MD , Timothy W. Neal DDS, MD , Patricia Sarcos DMD, MD , Scott Bueno DDS, MD , Richard A. Finn DDS","doi":"10.1016/j.joms.2024.07.004","DOIUrl":"10.1016/j.joms.2024.07.004","url":null,"abstract":"<div><h3>Background</h3><div>Prophylactic antibiotics are routinely prescribed by surgeons for their patients who undergo septorhinoplasty. However, the literature to support this remains controversial, especially in complex cases, those that require grafts, revision cases, extended surgical time, and an American Society of Anesthesiologists (ASA) value greater than or equal to 3.</div></div><div><h3>Purpose</h3><div>The study purpose was to evaluate for a potential association between increased anesthetic complexity and the risk for surgical site infection (SSI) following complex septorhinoplasty.</div></div><div><h3>Study Design, Setting, Sample</h3><div>Retrospective cohort study of patients who underwent a complex septorhinoplasty between 2005 and 2022 at the Dallas Veterans Affairs Medical Center. Patients were excluded if they did receive a septorhinoplasty, did not follow up, or had insufficient records.</div></div><div><h3>Independent Variable</h3><div>All patients were assigned an ASA value prior to surgery, with an ASA value of 3 serving as this study's independent variable.</div></div><div><h3>Main Outcome Variable</h3><div>The main outcome variable of interest was the development of a postoperative SSI, defined as findings consistent with cellulitis, purulence, or fistula development necessitating antibiotic treatment.</div></div><div><h3>Covariates</h3><div>The demographic covariates included patient age and sex. Clinical covariates included diabetes status, history of nasal trauma or surgery, and smoking status. The operative covariates were surgical duration, perioperative antibiotic, intraoperative complication, and type of cartilage graft used.</div></div><div><h3>Analyses</h3><div>χ<sup>2</sup> Analysis and t-tests were used for calculations, with <em>P</em> values < .05 being considered significant.</div></div><div><h3>Results</h3><div>A total of 182 patients were included in this study, 81 (45%) with an ASA ≤2 and 101 (55%) with an ASA of 3. A patient's age (<em>P</em> < .01), male sex (<em>P</em> < .01), and a diagnosis of diabetes (<em>P</em> < .01) were associated with an ASA value of 3. In total, there were 6 (3.3%) SSIs, with 2 (1%) occurring in those with an ASA of 3. An ASA value of 3 (<em>P</em> = .27, relative risk of .40) was not shown to be associated with an increased risk of SSI.</div></div><div><h3>Conclusion and Relevance</h3><div>Our results suggest that an ASA of 3 is not significant with regard to postoperative infection in patients who undergo a complex nasal septorhinoplasty, and prophylactic postoperative antibiotics are not warranted.</div></div>","PeriodicalId":16612,"journal":{"name":"Journal of Oral and Maxillofacial Surgery","volume":"82 11","pages":"Pages 1373-1379"},"PeriodicalIF":2.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Oral Health Statistical Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: Manuscript Checklist 口腔健康研究观察性研究和临床试验报告 OHStat 指南：手稿核对表。

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.06.175

Al M. Best PhD , Thomas A. Lang MA , Barbara L. Greenberg PhD , John C. Gunsolley DDS, MS , Effie Ioannidou DMD, MS

Adequate and transparent reporting is necessary for critically appraising published research. Yet, ample evidence suggests that the design, conduct, analysis, interpretation, and reporting of oral health research could be greatly improved. Accordingly, the Task Force on Design and Analysis in Oral Health Research—statisticians and trialists from academia and industry—identified the minimum information needed to report and evaluate observational studies and clinical trials in oral health: the Oral Health Statistical (OHStat) Guidelines. Drafts were circulated to the editors of 85 oral health journals and to Task Force members and sponsors and discussed at a December 2020 workshop attended by 49 researchers. The guidelines were subsequently revised by the Task Force's writing group. The guidelines draw heavily from the Consolidated Standards for Reporting Trials, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), and Consolidated Standards for Reporting Trials harms guidelines and incorporate the Statistical Analysis and Methods in Published Literature guidelines for reporting statistics, the Clinical and Laboratory Images in Publications principles for documenting images, and the Grading of Recommendations Assessment, Development and Evaluation indicating the quality of evidence. The guidelines also recommend reporting estimates in clinically meaningful units using confidence intervals, rather than relying on P values. In addition, OHStat introduces 7 new guidelines that concern the text itself, such as checking the congruence between abstract and text, structuring the discussion, and listing conclusions to make them more specific. OHStat does not replace other reporting guidelines; it incorporates those most relevant to dental researches into a single document. Manuscripts using the OHStat guidelines will provide more information specific to oral health research.

充分而透明的报告对于批判性地评估已发表的研究是必要的。然而，大量证据表明，口腔健康研究的设计、实施、分析、解释和报告都可以大大改进。因此，口腔健康研究设计与分析工作组--来自学术界和工业界的统计学家和试验专家--确定了报告和评估口腔健康观察研究和临床试验所需的最低限度信息：口腔健康统计（OHStat）指南。指南草案已分发给 85 份口腔健康期刊的编辑以及特别工作组成员和赞助商，并在 2020 年 12 月举行的研讨会上进行了讨论，49 名研究人员参加了此次研讨会。随后，工作组的写作小组对指南进行了修订。该指南在很大程度上借鉴了《试验报告综合标准》、《加强流行病学观察性研究报告》（STROBE）和《试验危害报告综合标准》指南，并纳入了《发表文献中的统计分析和方法》指南以报告统计数据，《出版物中的临床和实验室图像》原则以记录图像，以及《建议分级评估、发展和评价》以说明证据质量。该指南还建议使用置信区间以对临床有意义的单位报告估计值，而不是依赖 P 值。此外，OHStat 还引入了 7 项与文本本身有关的新指南，如检查摘要与文本之间的一致性、安排讨论的结构、列出结论使其更具体等。OHStat并不取代其他报告指南，而是将与口腔医学研究最相关的指南整合到一份文件中。使用OHStat指南的稿件将提供更多口腔健康研究的具体信息。

{"title":"The Oral Health Statistical Guidelines for Reporting Observational Studies and Clinical Trials in Oral Health Research: Manuscript Checklist","authors":"Al M. Best PhD , Thomas A. Lang MA , Barbara L. Greenberg PhD , John C. Gunsolley DDS, MS , Effie Ioannidou DMD, MS","doi":"10.1016/j.joms.2024.06.175","DOIUrl":"10.1016/j.joms.2024.06.175","url":null,"abstract":"<div><div>Adequate and transparent reporting is necessary for critically appraising published research. Yet, ample evidence suggests that the design, conduct, analysis, interpretation, and reporting of oral health research could be greatly improved. Accordingly, the Task Force on Design and Analysis in Oral Health Research—statisticians and trialists from academia and industry—identified the minimum information needed to report and evaluate observational studies and clinical trials in oral health: the Oral Health Statistical (OHStat) Guidelines. Drafts were circulated to the editors of 85 oral health journals and to Task Force members and sponsors and discussed at a December 2020 workshop attended by 49 researchers. The guidelines were subsequently revised by the Task Force's writing group. The guidelines draw heavily from the Consolidated Standards for Reporting Trials, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), and Consolidated Standards for Reporting Trials harms guidelines and incorporate the Statistical Analysis and Methods in Published Literature guidelines for reporting statistics, the Clinical and Laboratory Images in Publications principles for documenting images, and the Grading of Recommendations Assessment, Development and Evaluation indicating the quality of evidence. The guidelines also recommend reporting estimates in clinically meaningful units using confidence intervals, rather than relying on <em>P</em> values. In addition, OHStat introduces 7 new guidelines that concern the text itself, such as checking the congruence between abstract and text, structuring the discussion, and listing conclusions to make them more specific. OHStat does not replace other reporting guidelines; it incorporates those most relevant to dental researches into a single document. Manuscripts using the OHStat guidelines will provide more information specific to oral health research.</div></div>","PeriodicalId":16612,"journal":{"name":"Journal of Oral and Maxillofacial Surgery","volume":"82 11","pages":"Pages 1494-1501"},"PeriodicalIF":2.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141711102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Affects Healing Rates in Patients Treated for Medication-Related Osteonecrosis of the Jaw? The Role of Operative Therapy and Other Clinical Factors 是什么影响了药物性颌骨骨坏死患者的愈合率？手术治疗和其他临床因素的作用。

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.06.176

Masaki Fujimori DDS , Yoshiyuki Toriyabe DDS , Noriyuki Sakakibara DDS, PhD , Masanori Nojima MD, PhD, MPH , Shujiroh Makino DDS, PhD

Background

In the therapy of medication-related osteonecrosis of the jaw (MRONJ), the healing rate, effectiveness of operative therapy, and factors associated with healing remain unclear.

Purpose

This study aimed to estimate MRONJ therapy healing rates and identify associated prognostic factors.

Study Design, Setting, Sample

A 25-center prospective cohort study was conducted on 291 patients with MRONJ treated with a common therapeutic protocol during 2013–2016. Patients unable to continue examinations or treatment were excluded.

Predictor Variable

The primary predictor variable was MRONJ therapy grouped into two categories: operative and nonoperative. Secondarily, the prognostic factors categorized as demographic, medical, clinical, and perioperative were evaluated.

Main Outcome Variables

The primary outcome variable was treatment duration, defined as the time (in months) between the initiation of therapy and when the site was healed or the date of the final visit or loss to follow-up.

Covariates

Not applicable.

Analyses

Descriptive statistics and 3-year cumulative healing rates were calculated. The association between clinical factors and time to healing was analyzed using bivariate and multivariate analyses and propensity score analysis. P < .05 was considered significant.

Results

We analyzed data from 291 subjects with 76 (26.1%) and 215 (73.9%) subjects in the operative and nonoperative therapy groups, respectively. The healing rates for operative and nonoperative therapies were 95.8 and 70.7%, respectively (hazard ratio [HR] = 1.6, 95% confidence interval [CI] = 1.1–2.2, P value [P] < .01). The healing rates in patients for whom anti-resorptive agent (ARA) treatment was discontinued and continued were 87.2 and 37.4%, respectively (HR = 1.8, 95% CI = 1.1–3.0, P = .02). In a multiple regression analysis using ARA indication, the therapy method showed a significant association in the MRONJ malignancy group (HR = 2.75, 95% CI = 1.46–5.17, P < .01).

Conclusion and Relevance

Operative therapy and ARA discontinuation were associated with better healing rates in MRONJ therapy. However, the choice of therapy for MRONJ should be based on a comprehensive consideration of the patient's condition. ARA discontinuation should be considered an adjunctive measure because of the possibility of adverse events such as fragility fractures and skeletal related events.

背景：在药物相关性颌骨坏死（MRONJ）的治疗中，愈合率、手术治疗的有效性以及与愈合相关的因素仍不清楚。研究目的：本研究旨在估算MRONJ治疗的愈合率，并确定相关的预后因素：研究设计、环境和样本：2013-2016年间，一项25个中心的前瞻性队列研究对291名接受普通治疗方案治疗的MRONJ患者进行了研究。无法继续检查或治疗的患者被排除在外：主要预测变量是 MRONJ 治疗，分为手术和非手术两类。其次，还评估了分为人口统计学、医学、临床和围手术期的预后因素：主要结果变量是治疗持续时间，定义为从开始治疗到治疗部位愈合或最后就诊或失去随访机会的日期之间的时间（以月为单位）：不适用：分析：计算描述性统计数字和3年累积愈合率。采用双变量和多变量分析以及倾向评分分析法分析了临床因素与愈合时间之间的关系。P 结果：我们分析了 291 例受试者的数据，其中手术组和非手术治疗组分别有 76 例（26.1%）和 215 例（73.9%）受试者。手术和非手术疗法的治愈率分别为 95.8% 和 70.7%（危险比 [HR] = 1.6，95% 置信区间 [CI] = 1.1-2.2，P 值 [P] 结论和相关性：在 MRONJ 治疗中，手术治疗和停用 ARA 与更好的愈合率相关。然而，MRONJ疗法的选择应基于对患者病情的综合考虑。由于可能出现脆性骨折和骨骼相关事件等不良反应，停用 ARA 应被视为一种辅助措施。

{"title":"What Affects Healing Rates in Patients Treated for Medication-Related Osteonecrosis of the Jaw? The Role of Operative Therapy and Other Clinical Factors","authors":"Masaki Fujimori DDS , Yoshiyuki Toriyabe DDS , Noriyuki Sakakibara DDS, PhD , Masanori Nojima MD, PhD, MPH , Shujiroh Makino DDS, PhD","doi":"10.1016/j.joms.2024.06.176","DOIUrl":"10.1016/j.joms.2024.06.176","url":null,"abstract":"<div><h3>Background</h3><div>In the therapy of medication-related osteonecrosis of the jaw (MRONJ), the healing rate, effectiveness of operative therapy, and factors associated with healing remain unclear.</div></div><div><h3>Purpose</h3><div>This study aimed to estimate MRONJ therapy healing rates and identify associated prognostic factors.</div></div><div><h3>Study Design, Setting, Sample</h3><div>A 25-center prospective cohort study was conducted on 291 patients with MRONJ treated with a common therapeutic protocol during 2013–2016. Patients unable to continue examinations or treatment were excluded.</div></div><div><h3>Predictor Variable</h3><div>The primary predictor variable was MRONJ therapy grouped into two categories: operative and nonoperative. Secondarily, the prognostic factors categorized as demographic, medical, clinical, and perioperative were evaluated.</div></div><div><h3>Main Outcome Variables</h3><div>The primary outcome variable was treatment duration, defined as the time (in months) between the initiation of therapy and when the site was healed or the date of the final visit or loss to follow-up.</div></div><div><h3>Covariates</h3><div>Not applicable.</div></div><div><h3>Analyses</h3><div>Descriptive statistics and 3-year cumulative healing rates were calculated. The association between clinical factors and time to healing was analyzed using bivariate and multivariate analyses and propensity score analysis. <em>P</em> < .05 was considered significant.</div></div><div><h3>Results</h3><div>We analyzed data from 291 subjects with 76 (26.1%) and 215 (73.9%) subjects in the operative and nonoperative therapy groups, respectively. The healing rates for operative and nonoperative therapies were 95.8 and 70.7%, respectively (hazard ratio [HR] = 1.6, 95% confidence interval [CI] = 1.1–2.2, <em>P</em> value [<em>P</em>] < .01). The healing rates in patients for whom anti-resorptive agent (ARA) treatment was discontinued and continued were 87.2 and 37.4%, respectively (HR = 1.8, 95% CI = 1.1–3.0, <em>P</em> = .02). In a multiple regression analysis using ARA indication, the therapy method showed a significant association in the MRONJ malignancy group (HR = 2.75, 95% CI = 1.46–5.17, <em>P</em> < .01).</div></div><div><h3>Conclusion and Relevance</h3><div>Operative therapy and ARA discontinuation were associated with better healing rates in MRONJ therapy. However, the choice of therapy for MRONJ should be based on a comprehensive consideration of the patient's condition. ARA discontinuation should be considered an adjunctive measure because of the possibility of adverse events such as fragility fractures and skeletal related events.</div></div>","PeriodicalId":16612,"journal":{"name":"Journal of Oral and Maxillofacial Surgery","volume":"82 11","pages":"Pages 1441-1455"},"PeriodicalIF":2.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral TMJ Osteoarthritic Destruction, Arthralgia, and Hearing Loss: A Case report on a Mysteriously Aggressive and Invasive Disease 双侧颞下颌关节骨关节炎破坏、关节痛和听力损失：关于一种神秘的侵袭性侵袭性疾病的病例报告

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.08.020

Johnson Cheung DDS, MD, MSc, MSc, FRCD(C), Sharon Aronovich DMD, FACS, FRCD(C), Johnson Cheung DDS, MD, MSc, MSc, FRCD(C) (Presenter)

引用次数: 0

Planning the Cut: Gender-Affirming Considerations in Orthognathic Surgery 规划切口：正颌外科手术中的性别平等考虑因素。

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.07.017

Elda L. Fisher DMD, MD, FACS , Shane Morrison MD, MS, FACS , Srinivas M. Susarla MD, DMD, MPH, FACS, FAAP , Russell Ettinger MD, FACS

引用次数: 0

Predicting Outcomes of Decompression Therapy in Odontogenic Keratocysts 预测牙源性角化囊肿减压疗法的疗效

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.08.027

Karl Cuddy BSc, DDS, MD, MSc, FRCD(C), Jeffrey Chadwick DDS, Lynley McIntee, Karl Cuddy BSc, DDS, MD, MSc, FRCD(C) (Presenter)

引用次数: 0

The Number of Positive Lymph Nodes Instead of Extranodal Extension and Nodal Diameter is an Independent Predictor of Survival and Treatment Outcome of High-Grade Parotid Gland Carcinoma 阳性淋巴结数量而非结节外扩展和结节直径是高级别腮腺癌生存率和治疗效果的独立预测指标

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.06.179

Denis Brajkovic DMD, PhD , Aleksandar Kiralj DMD, PhD , Miroslav Ilic MD, DMD, PhD , Ivana Mijatov MD, PhD , Borivoj Bijelic DMD, PhD

<div><h3>Background</h3><div>There is emerging evidence that current 8<sup>th</sup> edition of the American Joint Committee staging system is not sensitive enough to predict parotid gland carcinoma (PGC) survival outcomes.</div></div><div><h3>Purpose</h3><div>The present study aimed to analyze pathological nodal factors related to survival and treatment outcomes in a cohort of patients surgically treated with PGC.</div></div><div><h3>Study Design, Setting, Sample</h3><div>We performed a retrospective cohort study of consecutive patients surgically treated with PGC at the authors' institution from January 1993 to December 2018. The inclusion criteria were as follows: confirmed high-grade parotid gland malignancy on histopathology first surgical treatment of the parotid cancer with neck dissection with curative intent at the study clinic; and sufficient data for review. The exclusion criteria were previous treatment in another institution, low-grade carcinomas, cases where neck dissection was not performed, incurable local disease and distant metastases at the time of first diagnosis, and patients lost to follow-up.</div></div><div><h3>Predictor Variable</h3><div>Predictor variable comprised pathological nodal factors grouped as the number of cervical node metastases, extranodal extension (ENE), largest diameter of nodal metastasis, and involvement of parotid lymph nodes.</div></div><div><h3>Main Outcome Variables</h3><div>Outcomes evaluated were overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), locoregional recurrence-free survival, and distant metastasis-free survival (DMFS). OS was calculated from the day of biopsy or definitive surgery to the last known hospital follow-up date or the date of death found in the hospital records or social security data. DSS was calculated from the day of biopsy or definitive surgery until the last known follow-up or death from PGC reported in the patient record. Patients who died from causes other than the disease being studied are not counted in this measurement. Treatment outcome was evaluated through the occurrence of locoregional relapse of the disease or development of distant metastases. RFS was defined as the time from the date of biopsy or definitive surgery to the date of locoregional recurrence free survivalor DMFS reported in the patient record.</div></div><div><h3>Covariates</h3><div>Covariates were composed of a set of heterogeneous variables grouped into the following categories: demographic, pathologic, and clinical.</div></div><div><h3>Analyses</h3><div>Unadjusted and adjusted hazard ratios for each variable were calculated with univariate and multivariable Cox regression. The tatistical significance was defined at a <em>P</em> value of < .05.</div></div><div><h3>Results</h3><div>The cohort of 112 patients included 62 males (55%) and 50 (45%) females. The mean age of the patients was 60.52 ± 15.22 years. The median follow-up time was 59 months (3-221 months

背景：有新证据表明，目前的第8版美国联合委员会分期系统对预测腮腺癌（PGC）的生存结果不够敏感。研究目的：本研究旨在分析一组接受手术治疗的PGC患者中与生存和治疗结果相关的病理结节因素：我们对 1993 年 1 月至 2018 年 12 月期间在作者所在机构接受 PGC 手术治疗的连续患者进行了回顾性队列研究。纳入标准如下：组织病理学确诊为高级别腮腺恶性肿瘤；在研究诊所首次接受腮腺癌手术治疗，并以治愈为目的进行了颈部切除术；有足够的数据可供回顾。排除标准包括：曾在其他机构接受过治疗、低分化癌、未进行颈部切除术、首次确诊时存在无法治愈的局部疾病和远处转移以及失去随访的患者：预测变量包括病理结节因素，分为颈部结节转移数量、结节外扩展（ENE）、结节转移的最大直径和腮腺淋巴结受累：评估的结果包括总生存期（OS）、疾病特异性生存期（DSS）、无复发生存期（RFS）、无局部复发生存期和无远处转移生存期（DMFS）。OS的计算时间为活检或明确手术（S）当日至最后已知的医院随访日期或在医院记录或社会保障数据中找到的死亡日期。DSS的计算时间为活检或明确手术（S）当日至最后一次已知的随访日期或患者病历中报告的PGC死亡日期。因研究疾病以外的其他原因死亡的患者不计入本次测量。治疗结果通过疾病的局部复发或远处转移来评估。RFS是指从活检或确定S之日起至患者病历中报告的无局部复发生存期或DMFS之日止的时间：协变量由一组异质性变量组成，分为以下几类：人口统计学变量、病理学变量和临床变量：通过单变量和多变量 Cox 回归计算每个变量的未调整和调整后危险比。统计显著性的定义是 P 值为结果：112 名患者中有 62 名男性（55%）和 50 名女性（45%）。患者的平均年龄为 60.52 ± 15.22 岁。中位随访时间为 59 个月（3-221 个月）。腺样囊性癌是最常见的肿瘤类型，发病率为45%。随访5年和10年的累积OS分别为75%和61%。27名患者（24%）出现局部复发，25名患者（22%）出现远处转移，5名患者（6%）同时确诊为局部复发和远处转移。转移性结节的数量是与OS（P = .02；HR = 2.67；CI = 0.03-6.35）、DSS（P = .011；HR = 2.55；CI = .61-6.83）和DMFS（P = .005；HR = 2.85；CI = 0.12-4.76）相关的最重要的结节预后因素。病理腮腺结节的存在与较差的RFS相关（P = .015；HR = 3.45；CI = 0.25-6.02）：转移淋巴结的数量，而不是ENE和最大结节直径，是与手术治疗的高级别PGC患者的生存和治疗效果相关的因素。由于分期系统的主要功能是预测预后，因此ENE和结节直径在唾液腺癌分期系统中的意义需要进一步明确。本研究的一个重要发现是，腮腺淋巴结阳性与局部治疗失败有关。

{"title":"The Number of Positive Lymph Nodes Instead of Extranodal Extension and Nodal Diameter is an Independent Predictor of Survival and Treatment Outcome of High-Grade Parotid Gland Carcinoma","authors":"Denis Brajkovic DMD, PhD , Aleksandar Kiralj DMD, PhD , Miroslav Ilic MD, DMD, PhD , Ivana Mijatov MD, PhD , Borivoj Bijelic DMD, PhD","doi":"10.1016/j.joms.2024.06.179","DOIUrl":"10.1016/j.joms.2024.06.179","url":null,"abstract":"<div><h3>Background</h3><div>There is emerging evidence that current 8<sup>th</sup> edition of the American Joint Committee staging system is not sensitive enough to predict parotid gland carcinoma (PGC) survival outcomes.</div></div><div><h3>Purpose</h3><div>The present study aimed to analyze pathological nodal factors related to survival and treatment outcomes in a cohort of patients surgically treated with PGC.</div></div><div><h3>Study Design, Setting, Sample</h3><div>We performed a retrospective cohort study of consecutive patients surgically treated with PGC at the authors' institution from January 1993 to December 2018. The inclusion criteria were as follows: confirmed high-grade parotid gland malignancy on histopathology first surgical treatment of the parotid cancer with neck dissection with curative intent at the study clinic; and sufficient data for review. The exclusion criteria were previous treatment in another institution, low-grade carcinomas, cases where neck dissection was not performed, incurable local disease and distant metastases at the time of first diagnosis, and patients lost to follow-up.</div></div><div><h3>Predictor Variable</h3><div>Predictor variable comprised pathological nodal factors grouped as the number of cervical node metastases, extranodal extension (ENE), largest diameter of nodal metastasis, and involvement of parotid lymph nodes.</div></div><div><h3>Main Outcome Variables</h3><div>Outcomes evaluated were overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), locoregional recurrence-free survival, and distant metastasis-free survival (DMFS). OS was calculated from the day of biopsy or definitive surgery to the last known hospital follow-up date or the date of death found in the hospital records or social security data. DSS was calculated from the day of biopsy or definitive surgery until the last known follow-up or death from PGC reported in the patient record. Patients who died from causes other than the disease being studied are not counted in this measurement. Treatment outcome was evaluated through the occurrence of locoregional relapse of the disease or development of distant metastases. RFS was defined as the time from the date of biopsy or definitive surgery to the date of locoregional recurrence free survivalor DMFS reported in the patient record.</div></div><div><h3>Covariates</h3><div>Covariates were composed of a set of heterogeneous variables grouped into the following categories: demographic, pathologic, and clinical.</div></div><div><h3>Analyses</h3><div>Unadjusted and adjusted hazard ratios for each variable were calculated with univariate and multivariable Cox regression. The tatistical significance was defined at a <em>P</em> value of < .05.</div></div><div><h3>Results</h3><div>The cohort of 112 patients included 62 males (55%) and 50 (45%) females. The mean age of the patients was 60.52 ± 15.22 years. The median follow-up time was 59 months (3-221 months","PeriodicalId":16612,"journal":{"name":"Journal of Oral and Maxillofacial Surgery","volume":"82 11","pages":"Pages 1456-1474"},"PeriodicalIF":2.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can the Upper Vermilion and the Nasolabial Fold Be Changed With Orthognathic Surgery? 正颌手术可以改变上朱唇和鼻唇沟吗？

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.07.010

Jocelyn S. Vivas-Castillo DDS, MSc , Adaia Valls-Ontañón MD, DDS, PhD , Federico J. Hernández-Alfaro MD, DDS, PhD

Background

Retrusive profiles show an appearance of aging with an under-projected vermilion and pronounced nasolabial folds due to deficient bone support.

Purpose

A study was made of the association between orthognathic surgery and changes in the nasolabial and vermilion areas in patients with retrusive profiles.

Study Design, Setting, Sample

A retrospective cohort study evaluated patients subjected to bimaxillary surgery according to the Barcelona Line (BL) protocol during 2021 at Teknon Medical Center (Barcelona, Spain). Subjects with craniofacial syndromes, facial esthetic procedures, and dental rehabilitations involving lip changes, were excluded.

Predictor Variable

The predictor variable was the timing of cephalometric measures, reported as T0 (preoperatively), T1 (1 month after surgery), and T2 (after 1 year of follow-up).

Main Outcome Variable

The outcome variable corresponded to the soft tissue changes of the nasolabial and vermilion area, reported as the nasolabial fold length and angle, nasolabial angle, upper lip concavity, vermilion length, and upper lip sagittal distance from BL.

Covariates

The covariates comprised patient demographic data, the surgical-orthodontic protocol, and the magnitude and direction of the skeletal movements.

Analyses

Descriptive and inferential analyses were performed based on analysis of variance, the Bonferroni test, Pearson's linear coefficient, the nonparametric Mann-Whitney U-test, Kruskal-Wallis test, and multiple linear regression models. Statistical significance was considered for P < .05.

Results

The sample comprised 27 subjects with a mean age of 32.5 ± 11.2 years. A mean decrease in nasolabial angle of 5.5 ± 6° was recorded (P < .001), with a shortening of the nasolabial fold length of 4.4 ± 7.6 mm (P = .019). An increase in upper lip concavity angle of 14.4 ± 12° was recorded (P < .001), along with a vermilion lengthening of 1.6 ± 1.3 mm (P < .001) and an increase in upper lip sagittal distance to BL of 5.7 ± 7.3 mm (P = .001), indicating a more projected and everted upper vermilion.

Conclusions and Relevance

When adequate dentoskeletal support is provided by specific positional changes of the jaws planned through orthognathic surgery, the length of the nasolabial fold decreases, and the upper vermilion lengthens and becomes slightly everted.

研究设计、设置、样本一项回顾性队列研究评估了2021年在Teknon医疗中心（西班牙巴塞罗那）根据巴塞罗那线（BL）方案接受双颌手术的患者。预测变量预测变量为头颅测量的时间，分别为 T0（术前）、T1（术后 1 个月）和 T2（随访 1 年后）。主要结果变量结果变量是鼻唇沟和朱砂区的软组织变化，报告为鼻唇沟长度和角度、鼻唇角、上唇凹陷、朱砂长度和上唇距BL的矢状距离。协变量协变量包括患者人口统计学数据、外科正畸方案以及骨骼移动的幅度和方向。分析根据方差分析、Bonferroni 检验、皮尔逊线性系数、非参数 Mann-Whitney U 检验、Kruskal-Wallis 检验和多元线性回归模型进行描述性和推论性分析。结果样本包括 27 名受试者，平均年龄为（32.5 ± 11.2）岁。鼻唇角平均缩小了 5.5 ± 6°（P < .001），鼻唇沟长度缩短了 4.4 ± 7.6 mm（P = .019）。上唇凹角增加了 14.4 ± 12°（P <.001），朱砂延长了 1.6 ± 1.3 mm（P <.001），上唇到基底的矢状距离增加了 5.7 ± 7.3 mm（P = .001），表明上唇朱砂更加突出和外翻。结论和相关性当通过正颌外科手术对颌骨进行特定的位置改变以提供足够的牙骨架支撑时，鼻唇沟的长度会减少，上唇会延长并略微外翻。

{"title":"Can the Upper Vermilion and the Nasolabial Fold Be Changed With Orthognathic Surgery?","authors":"Jocelyn S. Vivas-Castillo DDS, MSc , Adaia Valls-Ontañón MD, DDS, PhD , Federico J. Hernández-Alfaro MD, DDS, PhD","doi":"10.1016/j.joms.2024.07.010","DOIUrl":"10.1016/j.joms.2024.07.010","url":null,"abstract":"<div><h3>Background</h3><div>Retrusive profiles show an appearance of aging with an under-projected vermilion and pronounced nasolabial folds due to deficient bone support.</div></div><div><h3>Purpose</h3><div>A study was made of the association between orthognathic surgery and changes in the nasolabial and vermilion areas in patients with retrusive profiles.</div></div><div><h3>Study Design, Setting, Sample</h3><div>A retrospective cohort study evaluated patients subjected to bimaxillary surgery according to the Barcelona Line (BL) protocol during 2021 at Teknon Medical Center (Barcelona, Spain). Subjects with craniofacial syndromes, facial esthetic procedures, and dental rehabilitations involving lip changes, were excluded.</div></div><div><h3>Predictor Variable</h3><div>The predictor variable was the timing of cephalometric measures, reported as T0 (preoperatively), T1 (1 month after surgery), and T2 (after 1 year of follow-up).</div></div><div><h3>Main Outcome Variable</h3><div>The outcome variable corresponded to the soft tissue changes of the nasolabial and vermilion area, reported as the nasolabial fold length and angle, nasolabial angle, upper lip concavity, vermilion length, and upper lip sagittal distance from BL.</div></div><div><h3>Covariates</h3><div>The covariates comprised patient demographic data, the surgical-orthodontic protocol, and the magnitude and direction of the skeletal movements.</div></div><div><h3>Analyses</h3><div>Descriptive and inferential analyses were performed based on analysis of variance, the Bonferroni test, Pearson's linear coefficient, the nonparametric Mann-Whitney U-test, Kruskal-Wallis test, and multiple linear regression models. Statistical significance was considered for <em>P</em> < .05.</div></div><div><h3>Results</h3><div>The sample comprised 27 subjects with a mean age of 32.5 ± 11.2 years. A mean decrease in nasolabial angle of 5.5 ± 6° was recorded (<em>P</em> < .001), with a shortening of the nasolabial fold length of 4.4 ± 7.6 mm (<em>P</em> = .019). An increase in upper lip concavity angle of 14.4 ± 12° was recorded (<em>P</em> < .001), along with a vermilion lengthening of 1.6 ± 1.3 mm (<em>P</em> < .001) and an increase in upper lip sagittal distance to BL of 5.7 ± 7.3 mm (<em>P</em> = .001), indicating a more projected and everted upper vermilion.</div></div><div><h3>Conclusions and Relevance</h3><div>When adequate dentoskeletal support is provided by specific positional changes of the jaws planned through orthognathic surgery, the length of the nasolabial fold decreases, and the upper vermilion lengthens and becomes slightly everted.</div></div>","PeriodicalId":16612,"journal":{"name":"Journal of Oral and Maxillofacial Surgery","volume":"82 11","pages":"Pages 1386-1401"},"PeriodicalIF":2.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zygomatic Implant-Supported Reconstruction of Maxillectomy Defects 颧骨植入物支持的上颌骨切除术缺损重建术

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral and Maxillofacial Surgery

Pub Date : 2024-11-01 DOI: 10.1016/j.joms.2024.08.022

Michael J. Albdewi BS, Prashant Puttagunta BS, Noreen Khan BS, John Hennessy BS, Karthik Reddy BS, Jonathan Troost PhD, Stephanie M. Munz DDS, Joseph I. Helman DMD, Justine S. Moe MD, DDS, Justine S. Moe MD, DDS (Presenter)

引用次数: 0